Comparative Pharmacology
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus PROTRIPTYLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus PROTRIPTYLINE HYDROCHLORIDE.
CLOMIPRAMINE HYDROCHLORIDE vs PROTRIPTYLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, with additional anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. May also downregulate beta-adrenergic and serotonin receptors.
Oral, initial 25 mg three times daily; increase gradually to 100-250 mg/day in divided doses; maximum 300 mg/day for severe conditions.
15 mg orally 3 to 4 times daily, not to exceed 60 mg per day.
None Documented
None Documented
Terminal elimination half-life of clomipramine is 19-37 hours (mean ~30 hours); active metabolite desmethylclomipramine has half-life of 54-77 hours. Steady-state achieved within 1-2 weeks.
Terminal elimination half-life: 54-92 hours (mean ~74 hours); due to long half-life, steady-state is reached in 11-18 days.
Renal: ~60% (as conjugated metabolites and unchanged drug); Fecal: ~30% (biliary excretion); 2-3% excreted unchanged in urine.
Primarily renal (50-70% as metabolites, <5% unchanged); biliary/fecal elimination accounts for ~10-20%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant